Bristol-Myers Squibb Company’s Stock Price Drops to $59.01, Recording a 2.11% Decrease

Bristol-Myers Squibb Company (BMY)

59.01 USD -1.27 (-2.11%) Volume: 11.9M

Bristol-Myers Squibb Company’s stock price currently stands at 59.01 USD, experiencing a 2.11% decrease this trading session with a trading volume of 11.9M. Despite the recent dip, the pharmaceutical giant’s stock has seen a positive year-to-date (YTD) change of +4.33%, indicating steady growth for investors.

Latest developments on Bristol-Myers Squibb Company

Bristol-Myers Squibb (NYSE:BMY) has been making significant strides in the pharmaceutical industry, with recent events driving stock price movements. The European Commission has granted approval for the expanded use of their CAR T cell therapy, Breyanzi, for treating relapsed or refractory follicular lymphoma. Additionally, the company has acquired 2seventy bio in a $286 million deal, further enhancing their oncology portfolio. With positive news surrounding their innovative therapies and strategic acquisitions, investors are closely monitoring Bristol-Myers Squibb’s performance in the market.

A look at Bristol-Myers Squibb Company Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Bristol-Myers Squibb has a mixed long-term outlook. While the company scores high in Dividend and Momentum, indicating strong performance in these areas, it falls short in Value, Growth, and Resilience. This suggests that investors may see potential in Bristol-Myers Squibb’s dividend payouts and market momentum, but may have concerns about its overall value, growth potential, and resilience in the face of challenges.

Bristol-Myers Squibb Company is a global biopharmaceutical company that focuses on developing and selling pharmaceutical and nutritional products. Its portfolio includes products and experimental therapies for a range of health conditions such as cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders. Despite its strong performance in Dividend and Momentum according to Smartkarma Smart Scores, Bristol-Myers Squibb may need to address concerns in Value, Growth, and Resilience to secure a more stable long-term outlook.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma